

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
Geist William	BIO-TECHNE Corp [TECH]	(Check all applicable)
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Director 10% Owner
614 MCKINLEY PLACE NE	08/15/2026	X Officer (give title below) Other (specify below)
(Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)	PRESIDENT, PROTEIN SCIENCES
MINNEAPOLIS MN 55413		6. Individual or Joint/Group Filing (Check Applicable Line)
(City) (State) (Zip)		X Form filed by One Reporting Person
		Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/15/2026		M		6,416	A	\$0	26,919	D	
Common Stock	08/15/2026		F		1,976	D	\$72.4	24,943	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$100.39						(2)	02/01/2029	Common Stock	15,912		15,912	D	
Stock Options (Right to Buy)	\$94.52						(2)	08/15/2029	Common Stock	29,600		29,600	D	
Performance Restricted Stock Units	(1)	08/15/2026		M		567	(3)	(3)	Common Stock	567	\$0	8,507	D	
Performance Restricted Stock Units	(1)	08/15/2026		D		8,507	(3)	(3)	Common Stock	8,507	\$0	0	D	
Performance Stock Options (Right to Buy)	\$84.61	08/15/2026		D		22,898	(5)	(5)	Common Stock	22,898	\$0	1,526	D	
Stock Options (Right to Buy)	\$84.61						(4)	08/15/2030	Common Stock	30,059		30,059	D	
Performance Restricted Stock Units	(1)						(6)	(6)	Common Stock	15,738		15,738	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	08/15/2026		M			2,623	(7)	(7)	Common Stock	2,623	\$0	2,623	D	
Stock Options (Right to Buy)	\$74.91							(8)	08/15/2034	Common Stock	21,204		21,204	D	
Performance Restricted Stock Units	(1)							(9)	(9)	Common Stock	19,355		19,355	D	
Restricted Stock Units	(1)	08/15/2026		M			3,226	(10)	(10)	Common Stock	3,226	\$0	6,452	D	
Stock Options (Right to Buy)	\$53.6							(11)	08/15/2035	Common Stock	24,758		24,758	D	

Explanation of Responses:

- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 100% vested.
- On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited.
- Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
- On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited.
- Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.

[/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to 08/18/2026 Power of Attorney previously filed](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.